SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DR. BOND who wrote (2626)11/19/1997 7:27:00 AM
From: RT  Read Replies (1) of 23519
 
DR. BOND,

I'd say Vivus CEO Leland did an excellent job promoting Vivus..
Some importent issues clarified.
1. He didn't see any reason to lower the price for muse do to it's uniqueness in the market place. If you need aggressive therapy you have no other choice except caverjets needle therapy...
2. He said insurance reimbursement was over 70%.
3. He said they had 75 full time sales rep.to call on the HIGH Prescribing Physicians Groups.
4. He said his primary challenage was how to reach the primary care physican and that Vivus was test marketing a RENT A REP. PROGRAM to fulfill this need. So far the program was highly successful and would be expanded.

J Hemant Shah of HKS and CO. in my opinion was an absolute uninformed meathead. His comment that he though the market was only 5 million men was rediculious. Then he attempted to equate ED drugs to rogaine. What he failed to mention was that rogaine does not work so therefore the market never materialized.

RT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News